Author:
Boleslavská Tereza,Světlík Svatopluk,Žvátora Pavel,Bosák Jan,Dammer Ondřej,Beránek Josef,Kozlík Petr,Křížek Tomáš,Kutinová Canová Nikolina,Šíma Martin,Slanař Ondřej,Štěpánek František
Funder
Czech Science Foundation
Charles University Research Centre
Charles University
Subject
Pharmaceutical Science,General Medicine,Biotechnology
Reference30 articles.
1. Zytiga, EMA/CHMP/542871 – Assessment Report For Zytiga, EMA (European Medicines Agency), 2011.
2. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men;Acharya;Cancer Chemother. Pharmacol.,2012
3. Zytiga, NDA 202-379 Review – Abiraterone Acetate, FDA (U.S. Food and Drug administration), 2011.
4. Development of an abiraterone acetate formulation with improved oral bioavailability guided by absorption modeling based on in vitro dissolution and permeability measurements;Solymosi;Int. J. Pharm.,2017
5. Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect;Solymosi;Cancer Chemother. Pharmacol.,2017
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献